Clinical trial · Interventional
Laparoscopic Assisted Transanal Resection of Rectal Cancer With Total Mesorectal Excision
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rectal cancer is one of the frequent malignant neoplasms ,Total mesorectal excision (TME) has become the gold standard treatment for middle and lower rectal cancers. Laparoscopic TME still be difficult in patients with low rectal tumors, narrow pelvic anatomy, male sex or high body mass index . Difficult visualization of the pelvic anatomy along with the limitation of rigid laparoscopic instruments may affect the quality of oncological outcomes and increase the risks of injuries during surgery. A down to up approach via transanal total mesorectal excision (TaTME) technique may overcome these problems
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laparoscopic Assisted Transanal Total Mesorectal Excision | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- transanal TME
- description
- Laparoscopic Assisted Transanal Total Mesorectal Excision
- interventionNames
- Procedure: Laparoscopic Assisted Transanal Total Mesorectal Excision
Primary outcomes (1)
- measure
- intraoperative complication
- timeFrame
- 1 day
- description
- complication occured intraoperatively or on the first day of surgery
Secondary outcomes (7)
- measure
- resection margin
- timeFrame
- 1 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * • rectal cancer histologically proven through biopsy * tumours located at least 3 cm from anorectal ring; * local spread restricted to the rectal wall * adequate preoperative sphincter function and continence; * absence of distant metastases. * Suitable for elective surgical resection Exclusion Criteria: * • T4 tumours not responding to neoadjuvant chemo- radiotherapy * Patients under 18 years of age * Pregnancy * Previous rectal surgery (except local excision, endoscopic mucosal resection (EMR) or polypectomy) * Patients with acute intestinal obstruction * Multiple colorectal tumours * Familial Adenomatosis Polyposis Coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), Crohn's disease or ulcerative colitis * Planned synchronous abdominal organ resections * Preoperative evidence for distant metastases through imaging of the thorax and abdomen * Absolute contraindications to general anaesthesia, * presence of fecal incontinence, * undifferentiated tumors .
References
Publications (1)
- BACKGROUNDKang L, Chen WH, Luo SL, Luo YX, Liu ZH, Huang MJ, Wang JP. Transanal total mesorectal excision for rectal cancer: a preliminary report. Surg Endosc. 2016 Jun;30(6):2552-62. doi: 10.1007/s00464-015-4521-2. Epub 2015 Aug 27. PMID 26310534